Cynthia Alejandra Pastor Alvarez: aPTT or Anti-Xa to Monitor Unfractionated Heparin?
Cynthia Alejandra Pastor Alvarez, Clinical Pathologist at Almar Laboratories of arec Tecamachalco, shared a post on LinkedIn about a recent article by Isabelle Gouin-Thibault et al., published in Journal of Thrombosis and Haemostasis.
”TTaP or anti-Xa to monitor unfractionated heparin?
Monitoring of unfractionated heparin (UFH) continues to evolve.
The 2026 SSC guideline of the International Society on Thrombosis and Haemostasis (ISTH) considers the anti-factor Xa activity as the optimal test for routine monitoring of UFH, maintaining TTaP as an acceptable alternative.
Why is it relevant to the laboratory?
The aPTT is a functional test influenced by multiple variables independent of heparin concentration, including factor VIII, lupus anticoagulant, factor deficiencies, inflammation, and the characteristics of the reagent itself.
The determination of anti-Xa provides a more direct assessment of the anticoagulant effect of UFH, with a recommended therapeutic range of 0.30–0.70 U/mL for most indications.
This does not mean that the aPTT is no longer useful. When used, each laboratory must establish and validate its own therapeutic interval according to its analytical and reactive system.
An update that once again highlights the role of the clinical laboratory not only in the generation of results, but also in the selection and standardization of the methodology that best represents the patient’s condition.
Reference: Gouin-Thibault I, et al. How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH. J Thromb Haemost. 2026; 24:3051–3062.
Infographic made with the support of generative AI. Scientific content reviewed based on the SSC-ISTH 2026 guideline.”
Title: How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH
Authors: Isabelle Gouin-Thibault, Corinne Frere, Lana A Castellucci, Jean M Connors, Adam Cuker, Jerrold H Levy, Thomas Lecompte, Francois Mullier

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health